Mayo Clinic has taken an 11 percent ownership stake in the parent firm of Eden Prairie-based medtech startup NeuroOne Inc. as they collaborate on developing a new implantable system to treat epilepsy, Parkinson’s disease and other brain disorders, according to newly filed financial documents.
NeuroOne was founded in October to commercialize research developed at the University of Wisconsin and being advanced by Mayo. It revolves around a new kind of “thin film” electrode technology which, when implanted into the brain, is capable of quickly detecting irregular brain activity down to a single neuron, thus pinpointing the source of seizures and tremors.
